A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Arthritis and Rheumatism
Nicolino RupertoPediatric Rheumatology International Trials Organization

Abstract

To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m(2)/week) versus a higher dosage (30 mg/m(2)/week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/week). In the screening phase, 595 patients who were newly started on a standard dose of MTX were followed up for 6 months. Subsequently, the nonresponders, defined according to the American College of Rheumatology (ACR) pediatric 30% improvement criteria (pediatric 30), were randomized to receive an intermediate dose or higher dose of parenteral MTX for an additional 6 months. Improvement in the screening and randomization phase was defined by the ACR pediatric 30 response, as well as by the 50% and 70% response levels (ACR pediatric 50 and ACR pediatric 70, respectively). In the screening phase, after receiving standard doses of MTX, 430 patients (72%) improved according to the ACR pediatric 30, while 360 (61%) met the ACR pediatric 50 and 225 (38%) met the ACR pediatric 70; among these patients, 69 (12%) also met the definition of complete disease control. Of the 133 nonresponders, 80 were randomized to receive an intermediat...Continue Reading

References

Jun 1, 1991·The American Journal of Medicine·Q E Whiting-O'KeefeK D Sack
Jan 1, 1987·Cancer Chemotherapy and Pharmacology·A D PearsonJ M Chessells
Feb 1, 1986·Arthritis and Rheumatism·J T CassidyJ G Schaller
Mar 1, 1984·Clinical Pharmacology and Therapeutics·J EdelmanA S Russell
Dec 1, 1994·Arthritis and Rheumatism·G SinghD P Goldsmith
Mar 1, 1997·Annals of the Rheumatic Diseases·A RavelliA Martini
Jul 1, 1997·Arthritis and Rheumatism·E H GianniniA Martini
Aug 1, 1997·Rheumatic Diseases Clinics of North America·R Burgos-VargasJ Vázquez-Mellado
Jan 16, 2003·Arthritis and Rheumatism·Michelle PetriRobert A Brodsky

❮ Previous
Next ❯

Citations

May 12, 2006·Pediatric Radiology·Alison Jordan, Janet E McDonagh
Nov 16, 2011·Rheumatology International·A HeiligenhausUNKNOWN German Society for Rheumatology
Jun 21, 2005·Zeitschrift für Rheumatologie·F Weller, H-I Huppertz
Jul 16, 2010·Zeitschrift für Rheumatologie·D HolzingerD Föll
Aug 28, 2010·Zeitschrift für Rheumatologie·G Horneff
Mar 27, 2009·Clinical Rheumatology·María M Katsicas, Ricardo A G Russo
Oct 1, 2008·World Journal of Pediatrics : WJP·Nicolino Ruperto, Alberto Martini
Oct 7, 2009·Nature Reviews. Rheumatology·Claudia MacaubasElizabeth D Mellins
Apr 11, 2012·Nature Reviews. Rheumatology·Shirley M L Tse, Ronald M Laxer
Jul 11, 2013·Nature Reviews. Rheumatology·Daniel J LovellAlberto Martini
Aug 22, 2008·The New England Journal of Medicine·Daniel J LovellUNKNOWN Pediatric Rheumatology International Trials Organisation
Jun 27, 2012·Current Opinion in Rheumatology·Mara L Becker
Jan 1, 2013·Current Opinion in Rheumatology·Gerdien MijnheerFemke van Wijk
Mar 20, 2010·Annals of the Rheumatic Diseases·Nicolino RupertoUNKNOWN Pediatric Rheumatology Collaborative Study Group (PRCSG)
Aug 8, 2012·Therapeutic Advances in Musculoskeletal Disease·Natasha M Ruth, Murray H Passo
Feb 11, 2011·Molecular Medicine·Jelena Vojinovic, Nemanja Damjanov
Feb 23, 2011·Drug Design, Development and Therapy·Ofra Goldzweig, Philip J Hashkes
Aug 4, 2012·The Journal of Rheumatology·Timothy BeukelmanUNKNOWN CARRA Registry Investigators
May 23, 2013·Annals of the Rheumatic Diseases·Gerd HorneffUNKNOWN Paediatric Rheumatology International Trials Organisation (PRINTO)
May 2, 2014·Pediatric Rheumatology Online Journal·Matthew L Stoll, Randy Q Cron
Dec 19, 2013·Annals of the Rheumatic Diseases·Alessandro ConsolaroUNKNOWN Paediatric Rheumatology International Trials Organization (PRINTO)
Aug 22, 2014·Pediatric Rheumatology Online Journal·Mohamed AlbarouniGerd Horneff
Jun 30, 2014·Best Practice & Research. Clinical Rheumatology·Elizabeth A Kessler, Mara L Becker
Nov 10, 2006·Current Rheumatology Reports·Philip J Hashkes, Ronald M Laxer
Apr 29, 2010·Current Rheumatology Reports·Susan Shenoi, Carol A Wallace
Aug 27, 2009·Biologics : Targets & Therapy·Clare E Pain, Liza J McCann
Mar 27, 2013·Expert Opinion on Pharmacotherapy·Dawn M Wahezi, Norman T Ilowite
May 27, 2014·Expert Review of Clinical Immunology·Maja Bulatović Ćalasan, Nico M Wulffraat

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved